valsartan

Ligand id: 3937

Name: valsartan

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: valsartan

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 112.07
Molecular weight 435.23
XLogP 7.05
No. Lipinski's rules broken 2

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used as a single agent in the treatment of various cardiovascular conditions including hypertension, heart failure and diabetic nephropathy.

Fixed-dose combination drugs
Entresto®, a combination with sacubitril (a neprilysin inhibitor) is approved for heart failure.
Byvalson®, a combination drug containing nebivolol (5mg; a β1-adrenoceptor antagonist) and valsartan (80mg) was approved by the FDA in June 2016 for the treatment of hypertension.
Mechanism Of Action and Pharmacodynamic Effects
Inhibits the binding of angiotensin II to the AT1 receptor (AGTR1), thereby inhibiting the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to a decrease in vascular resistance and blood pressure.
External links